United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Because of the small number of patients and because the VEGF pathway was not interrogated, definitive conclusions about antiangiogenic effects of EZN-2968 in humans are difficult.
“However, given the small number of patients on the trial and the fact that interrogation of the VEGF pathway was not part of the study, it is difficult to draw definitive conclusions about the antiangiogenic effects of EZN-2968 in humans [20].”
From Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors (2014) · cites this paper as [20]
Section 6 discusses VEGFR-inhibiting kinase inhibitors and their adverse reactions, but not EZN-2968. Searches for EZN-2968 and its antiangiogenic effects returned no passage about its trial, patient number, or whether the VEGF pathway was interrogated. Our copy therefore does not establish the attributed conclusion. (LLM, conf=0.77)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · see citing works
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145 · see citing works
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974 · see citing works
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,606 · see citing works
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · see citing works
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848 · see citing works
O’Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T. H., Hochhaus, A., Hughes, T. P., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,550 · see citing works
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,426 · see citing works
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · see citing works
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · see citing works
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G. A., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,646 · see citing works
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, É., Dahan, L., Raoul, J., Bang, Y., Borbath, I., Lombard‐Bohas, C., Valle, J. W., Metrakos, P. P., Smith, D. M., Vinik, A. I., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567 · see citing works
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C. A., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,470 · see citing works
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S. M., Négrier, S., Szczylik, C. A., Пили, Р., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,182 · see citing works
van der Graaf, W. T. A., Blay, J., Chawla, S. P., Kim, D., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,103 · see citing works
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103 · see citing works
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079 · see citing works
Rini, B. I., Escudier, B. J., Tomczak, P., Каприн, А. Д., Szczylik, C. A., Hutson, T. E., Michaelson, M. D., Горбунова, В. А., Gore, M. E., Русаков, И. Г., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,843 · see citing works
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825 · see citing works
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712 · see citing works
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,703 · see citing works
Verweij, J., Casali, P. G., Zalcberg, J. R., Cesne, A. L., Reichardt, P., Blay, J., Issels, R. D., van Oosterom, A., Hogendoorn, P. C. W., Glabbeke, M. M. V., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17098-0 · Cited by 1,665 · see citing works
Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581 · see citing works
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H. M., Shah, N. P., Hochhaus, A., Cortes, J. E., Shah, S. A., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasqüini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,572 · see citing works
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567 · see citing works
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, É., Elisei, R., Jarząb, B., Vasselli, J. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,556 · see citing works
International Conference on Harmonisation
Guy, R. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,487 · see citing works
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Sekulić, A., Migden, M. R., Oro, A. E., Dirix, L. Y., Lewis, K. D., Hainsworth, J. D., Solomon, J. A., Yoo, S. S., Arron, S. T., Friedlander, P. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113713 · Cited by 1,460 · see citing works
DeMatteo, R. P., Ballman, K. V., Antonescu, C. R., Maki, R. G., Pisters, P. W. T., Demetri, G. D., Blackstein, M. E., Blanke, C. D., von Mehren, M., Brennan, M. F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60500-6 · Cited by 1,368 · see citing works
Camidge, D. R., Bang, Y., Kwak, E. L., Iafrate, A. J., Varella‐Garcia, M., Fox, S. B., Riely, G. J., Solomon, B., Ou, S. I., Kim, D., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70344-3 · Cited by 1,271 · see citing works
Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease
(2003) · Thyroid · doi:10.1089/105072503321086962 · Cited by 1,212 · see citing works
Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70112-1 · Cited by 1,186 · see citing works
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Staehler, M. D., Négrier, S., Chevreau, C., Desai, A. A., Rolland, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5511 · Cited by 1,087 · see citing works
Blanke, C. D., Rankin, C. J., Demetri, G. D., Ryan, C. W., von Mehren, M., Benjamin, R. S., Raymond, A. K., Bramwell, V. H. C., Baker, L. H., Maki, R. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.4452 · Cited by 1,074 · see citing works
Johnston, S. R. D., Pippen, J., Pivot, X. B., Lichinitser, M., Sadeghi, S., Dieras, V. C., Gómez, H., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,016 · see citing works
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor
Joensuu, H., Eriksson, M., Hall, K. S., Hartmann, J. T., Pink, D., Schütte, J., Ramadori, G. P., Hohenberger, P., Duyster, J., Al-Batran, S. E., et al. (2012) · JAMA · doi:10.1001/jama.2012.347 · Cited by 981 · see citing works
The Cytochrome P450 Superfamily: Biochemistry, Evolution and Drug Metabolism in Humans
Danielson, B. S. P. P. B. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337054 · Cited by 775 · see citing works
Deininger, M. W., O’Brien, S. G., Guilhot, F., Goldman, J. M., Hochhaus, A., Hughes, T. P., Radich, J. P., Hatfield, A. K., Mone, M. D., Filian, J., et al. (2009) · Blood · doi:10.1182/blood.v114.22.1126.1126 · Cited by 615 · see citing works
Kantarjian, H. M., Hochhaus, A., Saglio, G. N., Souza, C. A. D., Flinn, I. W., Stenke, L., Goh, Y. T., Rosti, G., Nakamae, H., Gallagher, N. J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70201-7 · Cited by 513 · see citing works
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2009) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 506 · see citing works
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2099 · Cited by 479 · see citing works
Cortes, J. E., Kantarjian, H. M., Brümmendorf, T. H., Kim, D., Turkina, A., Shen, Z.-X., Pasqüini, R., Khoury, H. J., Arkin, S., Volkert, A., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355594 · Cited by 462 · see citing works
Glabbeke, M. M. V., Owzar, K., Rankin, C. J., Simes, J. R., Crowley, J. J., & GIST Meta-analysis Group (MetaGIST) (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.10004 · Cited by 422 · see citing works
Maitland, M. L., Bakris, G. L., Black, H. R., Chen, H. X., Durand, J., Elliott, W. J., Ivy, S. P., Leier, C. V., Lindenfeld, J. M., Liu, G., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq091 · Cited by 410 · see citing works
Kantarjian, H. M., Giles, F. J., Bhalla, K. N., Pinilla-Ibarz, J. A., Larson, R. A., Gattermann, N., Ottmann, O. G., Hochhaus, A., Radich, J. P., Saglio, G. N., et al. (2010) · Blood · doi:10.1182/blood-2010-03-277152 · Cited by 379 · see citing works
Cameron, D., Casey, M., Oliva, C., Newstat, B. O., Imwalle, B., & Geyer, C. E. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0181 · Cited by 303 · see citing works
Brugger, W., Triller, N., Błasińska-Morawiec, M., Curescu, S., Sakalauskas, R., Manikhas, G. M., Mazières, J., Whittom, R., Ward, C., Mayne, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8162 · Cited by 280 · see citing works
Motzer, R. J., Hutson, T. E., Olsen, M. R., Hudes, G. R., Burke, J. M., Edenfield, W. J., Wilding, G., Agarwal, N., Thompson, J. A., Cella, D. F., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4133 · Cited by 275 · see citing works
American Thyroid Association Guidelines for Use of Laboratory Tests in Thyroid Disorders
Surks, M. I. (1990) · JAMA · doi:10.1001/jama.1990.03440110095035 · Cited by 274 · see citing works
Laboratory support for the diagnosis and monitoring of thyroid disease
Spencer, C. A. (2009) · Pathology · doi:10.1097/01268031-200941001-00041 · Cited by 202 · see citing works
Mechanisms, Risk Factors, and Management of Acquired Long QT Syndrome: A Comprehensive Review
Kallergis, E. M., Goudis, C. A., SIMANTIRAKIS, E. N., KOCHIADAKIS, G. E., & Vardas, P. E. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/212178 · Cited by 199 · see citing works
Demetri, G. D., Garrett, C. R., Schöffski, P., Shah, M. H., Verweij, J., Leyvraz, S., Hurwitz, H. I., Pousa, A. L., Cesne, A. L., Goldstein, D. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3005 · Cited by 138 · see citing works
Schöffski, P., Elisei, R., Müller, S. P., Brose, M. S., Shah, M. H., Licitra, L. F., Jarząb, B., Медведев, В. С., Kreissl, M. C., Niederle, B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.5508 · Cited by 92 · see citing works
Kollmannsberger, C., Bjarnason, G. A., Burnett, P., Creel, P. A., Davis, M. P., Dawson, N. A., Feldman, D. R., George, S., Hershman, J. M., Lechner, T., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0263 · Cited by 83 · see citing works
Kang, S. P., & Ratain, M. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0663 · Cited by 79 · see citing works
Patel, H. D., Egorin, M. J., Remick, S. C., Mulkerin, D. L., Takimoto, C. H. M., Doroshow, J. H., Potter, D., Ivy, S. P., Murgo, A. J., & Ramanathan, R. K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.6051 · Cited by 63 · see citing works
Self-citationTyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management
Brown, R. L. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0197-2 · Cited by 44 · see citing works
(2013) · Blood · doi:10.1182/blood-2013-08-524256 · Cited by 43 · see citing works
Pavlovsky, C., Egorin, M. J., Shah, D. D., Beumer, J. H., Rogel, S., & Pavlovsky, S. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.9.1152 · Cited by 42 · see citing works
Shah, N. P., Kantarjian, H. M., Kim, D., Hochhaus, A., Saglio, G. N., Guilhot, F., Schiffer, C. A., Steegmann, J. L., Mohamed, H., Dejardin, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.6506 · Cited by 36 · see citing works
Flagged first, then by citations
1 of the 64 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 843 · see citing works
Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
Chen, C., Wu, M.-Y., Ng, C. Y., Lu, C., Wu, J., Kao, P., Yang, C., Peng, M., Huang, C., Chang, W.-C., et al. (2018) · Cancer Management and Research · doi:10.2147/cmar.s163391 · Cited by 161 · see citing works
Jeong, W., Rapisarda, A., Park, S. R., Kinders, R. J., Chen, A., Melillo, G., Turkbey, B., Steinberg, S. M., Choyke, P., Doroshow, J. H., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2362-z · Cited by 159 · see citing works
“However, given the small number of patients on the trial and the fact that interrogation of the VEGF pathway was not part of the study, it is difficult to draw definitive conclusions about the antiangiogenic effects of EZN-2968 in humans [20].”
BackgroundSelf-citationHesham, H. M., Lasheen, D. S., & Abouzid, K. A. M. (2018) · Medicinal Research Reviews · doi:10.1002/med.21505 · Cited by 148 · see citing works
Antiangiogenic Effect of Flavonoids and Chalcones: An Update
Mirossay, L., Varinská, L., & Mojžíš, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010027 · Cited by 129 · see citing works
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors
Bass, A. K. A., El‐Zoghbi, M. S., Nageeb, E.-S. M., Mohamed, M. F. A., Badr, M., & Abuo‐Rahma, G. E. A. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112904 · Cited by 127 · see citing works
Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK)
Lu, Y., & Sun, H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01248 · Cited by 106 · see citing works
Translational research in oncology—10 years of progress and future prospects
Doroshow, J. H., & Kummar, S. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.158 · Cited by 89 · see citing works
Self-citationSmall molecule tyrosine kinase inhibitors in glioblastoma
Kim, G., & Ko, Y. T. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01232-3 · Cited by 82 · see citing works
Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer
Roy, R., Ria, T., RoyMahapatra, D., & Sk, U. H. (2023) · ACS Omega · doi:10.1021/acsomega.3c00222 · Cited by 79 · see citing works
The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea
Rugo, H. S., Palma, J. A. D., Tripathy, D., Bryce, R. P., Moran, S. E., Olek, E. A., & Bosserman, L. D. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-05102-x · Cited by 76 · see citing works
Targeting Molecular Inflammatory Pathways in Granuloma as Host-Directed Therapies for Tuberculosis
Guler, R., Ozturk, M., Sabeel, S., Motaung, B., Parihar, S. P., Thienemann, F., & Brombacher, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.733853 · Cited by 46 · see citing works
Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
Garrison, D. A., Talebi, Z., Eisenmann, E. D., Sparreboom, A., & Baker, S. D. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090856 · Cited by 49 · see citing works
Chen, C., Shenoy, A. K., Padia, R. N., Fang, D., Jing, Q., Yang, P., Su, S.-B., & Huang, S. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0902-4 · Cited by 47 · see citing works
The past, present, and future of chemotherapy with a focus on individualization of drug dosing
DeRidder, L. B., Rubinson, D. A., Langer, R., & Traverso, G. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.043 · Cited by 42 · see citing works
Dailah, H. G., Hommdi, A. A., Koriri, M. D., Algathlan, E. M., & Mohan, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24559 · Cited by 38 · see citing works
Garrido‐Cano, I., García-García, A., Péris-Vicente, J., Ochoa-Aranda, E., & Esteve‐Romero, J. S. (2015) · Talanta · doi:10.1016/j.talanta.2015.07.078 · Cited by 35 · see citing works
Advani, S., & Kopetz, S. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25441 · Cited by 34 · see citing works
Shawky, A. M., Ibrahim, N. A., Abourehab, M. A. S., Abdalla, A. N., & Gouda, A. M. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1837124 · Cited by 34 · see citing works
Adu-Gyamfi, C. G., Savulescu, D. M., George, J. A., & Suchard, M. S. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00372 · Cited by 33 · see citing works
Wolle, P., Hardick, J., Cronin, S. J. F., Engel, J., Baumann, M., Lategahn, J., Penninger, J. M., & Rauh, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00102 · Cited by 29 · see citing works
Rajendran, R. L., Paudel, S., Gangadaran, P., Oh, J. M., Oh, E. J., Hong, C. M., Lee, S., Chung, H. Y., Lee, J., & Ahn, B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020248 · Cited by 28 · see citing works
β-Escin Effectively Modulates HUVECs Proliferation and Tube Formation
Varinská, L., Fáber, L., Kello, M., Petrovová, E., Balážová, Ľ., Solár, P., Čoma, M., Urdzík, P., Mojžíš, J., Švajdlenka, E., et al. (2018) · Molecules · doi:10.3390/molecules23010197 · Cited by 27 · see citing works
Palakhachane, S., Ketkaew, Y., Chuaypen, N., Sirirak, J., Boonsombat, J., Ruchirawat, S., Tangkijvanich, P., Suksamrarn, A., & Limpachayaporn, P. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104831 · Cited by 26 · see citing works
Streubel, G., Schrepfer, S., Kallus, H., Parnitzke, U., Wulff, T., Hermann, F., Borgmann, M., & Hamm, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-88983-1 · Cited by 22 · see citing works
Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
Singh, B., Yang, S., Krishna, A., & Sridhar, S. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.594619 · Cited by 21 · see citing works
Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors
Panicker, R. C., Chattopadhaya, S., Coyne, A. G., & Srinivasan, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8719-7_11 · Cited by 21 · see citing works
Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice
Puhl, A. C., Gomes, G. F., Damasceno, S., Fritch, E. J., Levi, J. A., Johnson, N. J., Scholle, F., Premkumar, L., Hurst, B. L., Lee-Montiel, F., et al. (2022) · ACS Omega · doi:10.1021/acsomega.2c02794 · Cited by 18 · see citing works
Аrrousse, N., Harras, M. F., Kadiri, S. E., Haldhar, R., Ichou, H., Bousta, D., Grafov, A., Rais, Z., & Taleb, M. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.100996 · Cited by 18 · see citing works
Schöning, V., Krähenbühl, S., & Drewe, J. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.10.009 · Cited by 17 · see citing works
Sunitinib-induced oxidative imbalance and retinotoxic effects in rats
Garrido, Á. S., Reyes‐Goya, C., André, H., Aramburu, Ó., Mate, A., & Vázquez, C. M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118072 · Cited by 16 · see citing works
Prager, G., Unseld, M., Waneck, F., Mader, R., Wrba, F., Raderer, M., Fuereder, T., Staber, P., Jäger, U., Kieler, M., et al. (2019) · OncoTarget · doi:10.18632/oncotarget.26604 · Cited by 14 · see citing works
Croci, D. O., Méndez‐Huergo, S. P., Cerliani, J. P., & Rabinovich, G. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_29 · Cited by 14 · see citing works
Cuni, R., Parrini, I., Asteggiano, R., & Conte, M. R. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0460-5 · Cited by 12 · see citing works
Overcoming Resistance to Targeted Anticancer Drugs
Doroshow, J. H. (2013) · New England Journal of Medicine · doi:10.1056/nejme1311325 · Cited by 12 · see citing works
Self-citationSafety of available treatment options for renal cell carcinoma
Derosa, L., Albiges, L. K., Massard, C., Loriot, Y., Fizazi, K. S., & Escudier, B. J. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1184643 · Cited by 11 · see citing works
Michele, M. D., Stes, E., Vandermarliere, E., Arora, R., Astorga‐Wells, J., Vandenbussche, J., van Heerde, E., Zubarev, R. A., Bonnet, P., Linders, J. T. M., et al. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00282 · Cited by 11 · see citing works
Papadopoulos, K. P., Ben‐Ami, E., Patnaik, A., Trone, D., Li, J., & Demetri, G. D. (2018) · BMC Cancer · doi:10.1186/s12885-018-4692-z · Cited by 11 · see citing works
Mihajlović, M., Ivković, B. M., Jančić–Stojanović, B., Zeljković, A., Spasojević‐Kalimanovska, V., Kotur‐Stevuljević, J., & Vujanović, D. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000924 · Cited by 10 · see citing works
Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
Abecunas, C., Whitehead, C. E., Ziemke, E. K., Baumann, D. G., Frankowski-McGregor, C. L., Sebolt, J. S., & Fallahi‐Sichani, M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0883 · Cited by 9 · see citing works
Targeted Therapies in Cancer Treatment
Cavalcanti, I. D. L., & Soares, J. C. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-68334-4_5 · Cited by 7 · see citing works
Wang, F., Vasilyev, V., & Clayton, A. H. A. (2022) · New Journal of Chemistry · doi:10.1039/d1nj04348j · Cited by 6 · see citing works
Oral tyrosine kinase inhibitors in OMFS: a review
Shah, P. A., Dylgjeri, F., Srinivasan, B., & Brennan, P. A. (2020) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2019.11.022 · Cited by 5 · see citing works
Natural Compounds Targeting VEGFRs in Kidney Cancer: An In silico Prediction
Kuzu, B., & Karakuş, F. (2022) · Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi · doi:10.21597/jist.1108551 · Cited by 5 · see citing works
Ruxolitinib therapy for myelofibrosis in Austria
Krauth, M., Burgstaller, S., Buxhofer‐Ausch, V., Gastl, G. A., Geissler, K. H., Keil, F., Krippl, P., Melchardt, T., Petzer, A. L., Rumpold, H. F., et al. (2018) · Wiener klinische Wochenschrift · doi:10.1007/s00508-018-1365-5 · Cited by 5 · see citing works
Adenis, A., Mazard, T., Fraisse, J., Chalbos, P., Pastor, B., Evesque, L., Ghiringhelli, F., Mollévi, C., Delaine, S. C., & Ychou, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-08312-7 · Cited by 4 · see citing works
Computational Studies on Natural Products for the Development of Multi-target Drugs
Temml, V., & Schuster, D. (2018) · Methods in pharmacology and toxicology · doi:10.1007/7653_2018_18 · Cited by 4 · see citing works
Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected MicePreprint
Puhl, A. C., Gomes, G. F., Damasceno, S., Fritch, E. J., Levi, J. A., Johnson, N. J., Scholle, F., Premkumar, L., Hurst, B. L., Lee-Montiel, F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.16.472155 · Cited by 4 · see citing works
Progression of oncolytic virus in liver cancer treatment
Hua, X., Xuan, S., Tang, Y., You, S., Zhao, S., Qiu, Y., Li, Y., Li, Y., Su, Y., & Qu, P. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1446085 · Cited by 3 · see citing works
Mangat, P. K., Kirkwood, M. K., Hinshaw, D. C., Garrett-Mayer, E. S., & Schilsky, R. L. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00962-1 · Cited by 1 · see citing works
Abuarqoub, D. A., Al‐Sheikh, A., Mohammad, M., Khalaf, H., Albaz, N., & Hmedat, A. (2025) · RSC Advances · doi:10.1039/d5ra07478a · Cited by 1 · see citing works
Adenis, A., Ghiringhelli, F., Gauthier, L., Mazard, T., Evesque, L., Evrard, A., Chalbos, P., Moussion, A., Gourgou, S., & Ychou, M. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04682-4 · Cited by 1 · see citing works
Tyrosine kinase inhibitors for cancer treatment
Tullemans, B. M. E. (2021) · doi:10.26481/dis.20211006bt · Cited by 1 · see citing works
Utilizing Immunopet To Measure Tumor Response To Treatment In Breast Cancer
McKnight, B. N. (2019) · Human Biology
Anik, A. H., Rahman, M. S., & Sarker, S. (2022) · Oriental Journal Of Chemistry · doi:10.13005/ojc/380621
Data from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
Abecunas, C., Whitehead, C. E., Ziemke, E. K., Baumann, D. G., Frankowski-McGregor, C. L., Sebolt, J. S., & Fallahi‐Sichani, M. (2023) · doi:10.1158/0008-5472.c.6514230.v1
Hisham, N. S., Zain, W. N. I. W. M., Khan, J., Hasani, N. A. H., & Al-Talib, H. I. (2025) · Asia-Pacific Journal of Molecular Biology and Biotechnology · doi:10.35118/apjmbb.2025.033.3.10
BindingDB (2023) · UC San Diego · doi:10.7270/q2xp791q
BindingDB (2022) · UC San Diego · doi:10.7270/q24t6p31
- Authors
- Jeong, W., Doroshow, J. H., & Kummar, S.
- Affiliations
- New York Medical College (US)
- National Institutes of Health (US)
- Venue
- Current Problems in Cancer
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 37
- Issue
- 3
- Pages
- 110-144
- ISSN
- 0147-0272 (ISSN-L)
- PMC
- PMC3761410
- OpenAlex
- W2158933105
- Cited by
- 59
- References
- 64
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 8 · 2020: 9 · 2019: 7 · 2018: 9 · 2017: 4 · 2016: 2 · 2015: 2 · 2014: 1 · 2013: 2
- FWCI
- 0.12
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Current Problems in Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99 CA999999)
- National Cancer Institute (Y99 CA999999)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and biological activity
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and Characterization of Heterocyclic Compounds
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Keywords
- 1,2,3-triazoles, Huisgen 1,3-dipolar cycloaddition, nucleophilic aromatic substitution, hepatocellular carcinoma, VEGFR-2 inhibition, kinase inhibitors, selective cytotoxicity, cell migration inhibition, cell proliferation inhibition, anticancer agents
- MeSH terms
- Administration, Oral, Antineoplastic Agents, Humans, Neoplasms, United States, United States Food and Drug Administration, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
